Portola Pharma (PTLA) Tops Q1 EPS by 26c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.28), $0.26 better than the analyst estimate of ($1.54). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $3.9 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance